FP00-0043-00

Fig.1

30 A A C U C C U G U C U U G C A U U G C A C U A A G U C U U G C A C U U G U C A C A A C A G U G C A C C U A C U U C A A ACGTGATT CAGAACGTGAACAGTGTTTGTC 77-91 140 150 160 GUUCUA CA A A GA A A A CA CA GCUA CA A CUGGA GCA UUUA CUGCUG GA UUUA CA GA UGA UUU 200 210 220 230 190 UGA A UGGA A UUA A UA A U<u>UA CA A GA A UCCCA A A CUCA CCA GGA UGCUCA CA UUUA A GUUUU</u> ATGTT CTT AGGGTTT GAGTGGTC CTACGAGTGTA AATTCAAAA 198-212 213-227 228-242 260 280 290 A C A UG C C C A A G A A G G C C A C A G A A C UG A A A C A UC UUC A G UG UC UA G A A G A A G A A C U C A A A C TGTACGGGTTCTTCCGG TCTTCTTGAGTTTG 243-257 287-301 320 330 340 360 CUCUGGA GGA A GUGCUA A A UUUA GCUCA A A GCA A A A CUUUCA CUUA A GA CCCA GGGA CU GAGACCTCCTTCACGA GTGAATTCTGGGTCCCTGA 342-356 302-316 370 380 390 UA A UC A G C A A UA UC A A C GUA A UA GUUC UG GA A CUA A A G G G A UC UG A A A C A A C A UUC A UG U |ATTAGTCGTTA 357-371 450 460 GUGA A UA UGCUGA UGA GA CA GCA A CCA UUGUA GA A UUUCUGA A CA GA UGGA UUA CCUUUU 520 GUCAAAGCAUCAUCUCAACACUAACUUGAUAAUUAAGUGCUUCCCACUUAAAACAUAUCA 580 590 GGCCUUCUA UUUA UUUA A AUA UUUA A A UUUUA UA UUUA UUGUUGA A UGUA UGGUUUGCUA 630 C C D A U U G D A A C D A U D A U C U D A A U C U D A A A A C D A D A A D A U G G A U C U U U D A U G A U D U U 680 690 710 670 740 750 790 800 AUAAAUAUAAAAAAAAAAAC

FP00-0043-00

AGUUUUUGAUAGCUUUAUUUUUUAAGUAUUUUAUAUAUUUAUAACUCAUCAUAAAAUAAAG

610 UAUAUAUAGAAUCUAAAA

Fig.3




Fig.4




Fig.5




Fig.6





Fig.7








Fig.9




Fig.10




Fig.11




Fig.12





Fig.13


IL-2 342-356



RATIO OF AREAS 79.7%: 22.8%

Fig.14

IL-2 357-371



RATIO OF AREAS 72.7%: 27.3%

Fig.15

IL-4 119-133




Fig.16

IL-4 134-148





Fig.17






Fig.18

IL-4 280-294





Fig. 19



1 Time after adding 10 nM PMA, 0.5 mg/ml anti-human CD3 antibody and anti-human CD28 antibody to cultured Jurkat E6-1 cells

² The concentration of IL-2 in the culture supernatants measured by ELISA using anti-human IL-2 antibody

^{3, 4} Determination of cellular IL-2 expression level by dot blotting using RNA probe complementary to human IL-2 mRNA

Fig.20




Fig.21

IL-2 EXPRESSION (-) (+) PROBE IL-2 228-242(D) IL-2 243-257(A) IL-2 198-212(D) IL-2 213-227(A) IL-2 77-91(D) IL-2 92-106(A) IL-2 287-301(D) IL-2 302-316(A) IL-2 342-356(D) IL-2 357-371(A) NONE







Fig.23

IL-2 EXPRESSION






Fig.25




Fig.26




Fig.27




Fig.28




Fig.29




Fig.30





Fig.31








Fig.33




Fig.34





Fig.35








Fig.37




Fig.38




Fig.39




Fig.40




Fig.41




Fig.42




Fig.43




Fig.44




Fig.45




Fig.46




Fig.47



Fig.48




Fig.49




Fig.50





Fig.51



*Fig.*52






Fig.53








Fig.60




Fig.61




Fig.62




Fig.63




Fig.64




Fig.65




Fig.66




Fig.67




Fig.68




Fig.69




Fig.70




Fig.71




Fig.72




Fig.73





Fig.74

	A/A •	6 cells	D/A 1 cell
	D/D	5 cells	23 Je s

Fig.75








Fig.77




Fig.78




Fig.79




Fig.80




Fig.81




Fig.82




Fig.83




Fig.84




Fig.85




Fig.86

IL-2 mRNA (+); 5/24
IL-4 mRNA (+); 3/43

IL-4 mRNA (+); 0/10	IL-2 mRNA (+); 11/11
IL-5 mRNA (+); 0/11	γ -IF mRNA (+); 14/14
IL-10 mRNA (+); 0/9	IL-2 mRNA (+); 11/11 γ -IF mRNA (+); 14/14 TNF- β mRNA (+); 11/11

Fig.88

IL-2 mRNA (+); 6/28

IL-4 mRNA (+); 3/42

Fig.89

γ -IF mRNA (+); 0/11 TNF- eta mRNA (+); 0/9	IL-5 mRNA (+); 11/11 IL-10 mRNA (+); 11/11
)/11	1/1
.); (-	-
+) V	(+)
E Z	NS NS
Η	H H
- \times	<u> </u>
(+); 0/11	(+); 12/12
+); (• •
AR.	AN AN
IL-2 mRNA	IL-4 mRNA

Fig.90

IL-2 mRNA (+); 2/28	IL-2 mRNA (+); 3/35
IL-4 mRNA (+); 8/41	IL-4 mRNA (+); 9/42

Fig.91

6/6	6/0
TNF- /3 mRNA (+); 9/9	IL-10 mRNA (+); 0/9
6/6	8/0
γ -IF mRNA (+); 9/9	IL-5 mRNA (+); 0/8
IL-2 mRNA (+); 10/10	IL-4 mRNA (+); 0/9

Fig.92

IL-2 mRNA (+); 9/24	IL-2 mRNA (+); 11/29
IL-4 mRNA (+); 1/41	IL-4 mRNA (+); 1/48

Fig.93

γ -IF mRNA (+); 0/8 TNF- β mRNA (+); 0/8	IL-10 mRNA (+); 9/9
γ -IF mRNA (+); 0/8	IL-5 mRNA (+); 10/10
IL-2 mRNA (+); 0/7	IL-4 mRNA (+); 9/9

Fig.94

